ORPEA: Strong 2017 Revenue Growth of +10.5% to €3,138.2M, above GuidanceSource: Business Wire
Solid Organic Growth of +5.4%
Strong International Momentum, with Revenue up +19%
2018 Revenue Target: €3,400M (Growth of +8.3% Vs. 2017) Already Secured
|2017||2016||Change||Q4 2017||Q4 2016||Change|
|% of total revenue||57%||60%||56%||59%|
|% of total revenue||43%||40%||44%||41%|
Including organic growth 1
2017: revenue growth of 10.5%
In 2017, 15 years on from its IPO,
- a healthy organic growth of 5.4%, underpinned by the excellent performance of mature facilities, the ramp-up in facilities opened over the past two years and the opening of 1,900 new beds (through new builds and restructuration) during the year,
a dynamic external growth, leading to the acquisitions of Anavita in
Czech Republic, Dr. Dr. Wagner in Austria, Spitex in Switzerlandand independent facilities.
The international business again strongly contributed to revenue growth.
In only three years, revenue generated outside
In 2017, this fast-paced business development and growth went hand in hand with increasing profitability.
2018: sustained momentum in opening new beds (2,500) and job creation
Outlook for 2018: revenue target of €3,400 million
Yves Le Masne, Chief Executive Officer of
“Building on the commitment of our employees to deliver high-quality services worldwide, our loyal management team and our sound financial flexibility, we will continue to deliver profitable growth in 2018: selective acquisitions, revenue of €3,400 million already secured, and robust profitability, with an EBITDA margin (as a % of revenue) equal to or above its 2017 level.
Our tremendous potential for creating value comes from:
- the significant additions to our growing pipeline of beds under construction and redevelopment, which will fuel our organic growth in the future,
- our numerous attractive acquisition projects,
- an organisation and information system geared for international expansion.
We are now in a remarkably good position and are uniquely placed to accelerate our international expansion and become the world leader in long-term care.
Financial reporting schedule for 2018
The following dates can be subject to change. Press releases will be published after market close.
|Full-year 2017 results||Tuesday 27 March 2018|
|First-quarter 2018 sales||Wednesday 2 May 2018|
|Half-year 2018 sales||Tuesday 24 July 2018|
|Half-year 2018 results||Tuesday 25 September 2018|
|Third-quarter 2018 sales||Tuesday 6 November 2018|
Since its creation in 1989,
33,122 beds in
France(2,409 beds under construction or redevelopment) at 357 facilities
49,716 beds outside
France( Austria, Belgium, Brazil, China, Czech Republic, Germany, Italy, Poland, Portugal, Spainand Switzerland) at 441 facilities (9,962 beds under construction or redevelopment)
1 Organic growth is calculated based on an equivalent number of days to 2016 and reflects the following factors: 1. The year-on-year change in the revenues of existing facilities as a result of changes in their occupancy rates and daily rates; 2. The year-on-year change in the revenues of redeveloped facilities or those where the capacity has been increased in the current or year-earlier period; 3. Revenues generated in the current period by facilities created in the current or year-earlier period, and the change in revenues at recently acquired facilities by comparison with the previous equivalent period.
Yves Le Masne
Chief Executive Officer
Steve Grobet, Tel.: +33 (0)1 47 75 74 66
Investor and Media Relations:
Dusan Oresansky/Nicolas Merigeau, Tel.: +33 (0)1 44 71 94 94